IXHL supply chain intelligence for Incannex Healthcare Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| A-G-P-ALLIANCE-GLOBAL-PARTNERS | A-G-P-ALLIANCE-GLOBAL-PARTNERS | 90% | the Company, Curvature Securities, LLC ('Curvature') and A.G.P./Alliance Global Partners ('A.G.P.' and together with Curvature, the 'Sales Agents') |
| CONSULTANTS | CONSULTANTS | 90% | Our R&D expenses include: ● external costs incurred under agreements with contract research organizations, contract manufacturers, consultants and other third parties to conduct and support our clini… |
| CONTRACT-MANUFACTURERS | CONTRACT-MANUFACTURERS | 90% | Our R&D expenses include: ● external costs incurred under agreements with contract research organizations, contract manufacturers, consultants and other third parties to conduct and support our clini… |
| CONTRACT-RESEARCH-ORGANIZATIONS | CONTRACT-RESEARCH-ORGANIZATIONS | 90% | Our R&D expenses include: ● external costs incurred under agreements with contract research organizations, contract manufacturers, consultants and other third parties to conduct and support our clini… |
| CURVATURE-SECURITIES-LLC | CURVATURE-SECURITIES-LLC | 90% | the Company, Curvature Securities, LLC ('Curvature') and A.G.P./Alliance Global Partners ('A.G.P.' and together with Curvature, the 'Sales Agents') |
| MIND-MEDICINE-AUSTRALIA | MIND-MEDICINE-AUSTRALIA | 80% | The Company has a joint venture with Mind Medicine Australia ("MMA") to operate a psychedelic-assisted therapies services clinic in Melbourne, Australia |
| NVO | Novo Nordisk A/S | 72% | half from providing any bribe, gift or gratuity, including excessive or lavish meals, travel or entertainment in connection with marketing our products and services or securing required permits and a… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from IXHL graph: Reciprocal relationship from NVO graph: Reciprocal relationship from IXHL graph: Reciprocal relationship from NVO grap… |
| ORANY | ORANY | 72% | notice of the Federal Register publication is forwarded by the DEA to all those registered, or applicants for registration, as bulk manufacturers of that substance. Once registered, manufacturing fac… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IXHL graph: notice of the Federal Register publication is forwarded by the DEA to all those registered, or applicants for regist… |
| ARENA-INVESTORS | ARENA-INVESTORS | 70% | The (i) First Tranche Warrant, (ii) Registration Rights Agreement, dated as of October 14, 2025, by and between the Company and Arena Investors and (iii) ELOC Warrant remained in effect |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NVO | Novo Nordisk A/S | 72% | ed by the Court of Justice of the European Union (“CJEU”) in its decision on a case known as Schrems II , which invalidated the previous EU-US Privacy Shield. Notably, the new obligations were geared… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from IXHL graph: ed by the Court of Justice of the European Union (“CJEU”) in its decision on a case known as Schrems II , which invali… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IXHL graph: notice of the Federal Register publication is forwarded by the DEA to all those registered, or applicants for regist… |
| ORANY | ORANY | 72% | notice of the Federal Register publication is forwarded by the DEA to all those registered, or applicants for registration, as bulk manufacturers of that substance. Once registered, manufacturing fac… |
| CORPORATE-INFORMATION-INCANNEX-HEALTHCARE-INC | CORPORATE-INFORMATION-INCANNEX-HEALTHCARE-INC | 62% | ints raised by the Court of Justice of the European Union in its decision on a case known as Schrems II , which invalidated the previous EU-US Privacy Shield. Notably, the new obligations were geared… |
| EMERGING-GROWTH-COMPANY | EMERGING-GROWTH-COMPANY | 62% | gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the acquired set is not deemed to be a business and is instead acc… |
| FORMATION-ACQUISITION-JURISDICTION-INCANNEX-HEAL | FORMATION-ACQUISITION-JURISDICTION-INCANNEX-HEAL | 62% | ints raised by the Court of Justice of the European Union in its decision on a case known as Schrems II , which invalidated the previous EU-US Privacy Shield. Notably, the new obligations were geared… |
| SMALLER-REPORTING-COMPANY | SMALLER-REPORTING-COMPANY | 62% | gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the acquired set is not deemed to be a business and is instead acc… |
| SUBSIDIARY-JURISDICTION-INCANNEX-HEALTHCARE-PTY- | SUBSIDIARY-JURISDICTION-INCANNEX-HEALTHCARE-PTY- | 62% | current 163 113 Total current liabilities 5,620 2,550 Operating lease liabilities, non-current 210 408 Total liabilities 5,830 2,958 Commitments and contingencies (Note 8) Stockholders’ equity: Commo… |
| WORKING-GROUP | WORKING-GROUP | 62% | Cooperation Agreement between the European Union and the United Kingdom contains an Annex in relation to medicinal products with the objective of facilitating availability of medicines, promotion of … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IXHL-DEBT-10408 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-06-30. |
| IXHL-DEBT-10407 | Warrants outstanding: 453749 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| IXHL-DEBT | Debt stack $114,000 | 90% | Market cache reports total debt of $114,000. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 | |
| DWTX | Dogwood Therapeutics, Inc. | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 | |
| DFTX | Definium Therapeutics, Inc. | 50.00 | 2 | |
| CHUC | Charlie's Holdings, Inc. | 50.00 | 2 | |
| CLNE | Clean Energy Fuels Corp. | 50.00 | 2 | |
| FENC | Fennec Pharmaceuticals Inc. | 50.00 | 2 | |
| EQR | Equity Residential | 50.00 | 2 | |
| CNOB | ConnectOne Bancorp, Inc. | 50.00 | 2 | |
| DARE | Daré Bioscience, Inc. | 50.00 | 2 | |
| ESS | Essex Property Trust, Inc. | 50.00 | 2 | |
| ED | Consolidated Edison, Inc. | 50.00 | 2 | |
| SCNX | Scienture Holdings, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 |